FIRST LINE TREATMENT OF ADVANCED OVARIAN CANCER WITH PACLITAXEL/EPIRUBICIN/CARBOPLATIN (TEC) VS PACLITAXEL/CARBOPLATIN (TC). INTERIM RESULTS OF AN NSGO-EORT-GCG-NCIC-CTG GYNECOLOGICAL CANCER INTERGROUP PHASE III TRIAL

G. Stuart

doi:10.1136/ijgc-00009577-200303001-00020

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

ABSTRACTS: PLENARY SESSIONS: Session 4 – Ovary and Vulva

FIRST LINE TREATMENT OF ADVANCED OVARIAN CANCER WITH PACLITAXEL/EPIRUBICIN/CARBOPLATIN (TEC) VS PACLITAXEL/CARBOPLATIN (TC). INTERIM RESULTS OF AN NSGO-EORT-GCG-NCIC-CTG GYNECOLOGICAL CANCER INTERGROUP PHASE III TRIAL

	Abstract	Full	Pdf
May 2019	0	0	2
Sep 2019	0	0	3
Sep 2021	0	0	2
Jan 2022	0	0	2
Total	0	0	9

Main menu

Online download statistics by month:

Online download statistics by month: May 2019 to January 2022

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month: May 2019 to January 2022

Read the full text or download the PDF:

Log in using your username and password